Vertex Pharmaceuticals · 4 weeks ago
Vertex Summer Intern 2026, Preclinical Formulation
Vertex Pharmaceuticals is a global biotechnology company dedicated to tackling serious diseases and changing lives. The Preclinical Formulation internship program offers students the opportunity to work on meaningful projects, gain hands-on experience in formulation functional areas, and learn from industry leaders.
BiotechnologyHealth CareMedicalPharmaceutical
Responsibilities
Learning the day-to-day experiments of preclinical formulation experimentation
Running benchtop experiments using a wide variety of wet lab instruments including but not limited to pipettes, centrifuges, pH meters and analytical equipment
Learning liquid/solid handling software and hardware
Designing/coding liquid handling workflow
Qualification
Required
Enrolled in an undergraduate (Junior or Senior preferred but will consider underclass applicants with extensive experience) or graduate degree program and majoring in Pharmacy, Chemistry, Biochemistry, Chemical Engineering, Biochemical Engineering, Biomedical Engineering, or a related scientific field
Wet lab experience (pipetting, pH meter use, proper lab safety)
Basic coding knowledge (logic, loops, variable understanding and function understanding)
Excellent communication and presentation skills
Legal authorization to work in the United States, now and in the future. Please note that Vertex does not provide sponsorship for internships or entry level roles within this part of the organization
You must be available to work full-time, 40 hours per week from May – August 2026
Benefits
Free 24/7 onsite gym access and free access to group exercise classes
Subsidized commuter benefits- transit and parking
Provided meals—free breakfast daily!
Career development opportunities and events, including C Suite engagement
Social events—both intern-only and company-wide
Location-specific perks and extras!
Recognition of National Intern Day
Company
Vertex Pharmaceuticals
Vertex Pharmaceuticals is focused on the discovery and development of small molecule drugs for the treatment of serious diseases.
Funding
Current Stage
Public CompanyTotal Funding
$657.31MKey Investors
Janssen Belgium
2024-07-10Post Ipo Secondary· $1.11M
2022-05-17Post Ipo Equity· $50M
2009-12-03Post Ipo Equity· $443M
Leadership Team
Recent News
2026-01-05
Company data provided by crunchbase